Helps students develop critical skills.
Always patient, kind, and understanding.
Always clear, concise, and insightful.
Encourages open-minded and thoughtful discussions.
Great Professor!
Danielle Lang serves as a Research Academic in the School of Medicine and Public Health at the University of Newcastle, Australia. She earned her Bachelor of Mathematics and Bachelor of Economics from the University of Newcastle and a Postgraduate Diploma in Health Economics and Evaluation from Monash University. In her career, Lang has held the position of Course Coordinator at the University of Newcastle from January 2004 to September 2015. Currently, she leads the Newcastle Evaluation Group (NEG), which was founded in 1995 and stands as Australia's longest continuously operating university-based research group specializing in health technology assessment (HTA). The NEG conducts comprehensive economic evaluations for prominent bodies such as the Pharmaceutical Benefits Advisory Committee (PBAC), the Medicare Services Advisory Committee (MSAC), the Australian Technical Advisory Group on Immunisation (ATAGI), the National Diabetes Services Scheme (NDSS), and the Agency for Care Effectiveness (ACE) in Singapore. Additionally, the group performs Post-Market Reviews of PBS-subsidised medicines.
Lang's research interests are centered entirely on health economics, with expertise in economic evaluation, economic modelling, health economics, and pharmacoeconomics. She has been principal investigator or lead on 12 competitive grants totaling $30,296,308, including multi-year contracts from the Department of Health and Aged Care valued at over $8 million for PBAC submission evaluations and health technology assessments. Key examples include "The Provision Of External Evaluation Of Pharmaceutical Benefit Advisory Committee (PBAC) And Health Technology Related Submissions" ($8,085,426 in 2021) and similar prior contracts. Her scholarly output includes influential publications such as "Differential pricing of drugs: a role for cost-effectiveness analysis?" (The Lancet, 2002), a series of articles on the use of pharmacoeconomics in prescribing research published in the Journal of Clinical Pharmacy and Therapeutics (2003), "Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings" (BMC Pregnancy and Childbirth, 2015), and more recent works like "Economic Effects of Occupational Therapy Services for Adults in Acute and Subacute Care Settings: A Systematic Review" (American Journal of Occupational Therapy, 2022). Lang has also co-supervised doctoral research, including a 2021 PhD on the impact of diabetes on women's health outcomes. Her contributions have substantial impact on healthcare policy through evidence-based assessments that inform funding and reimbursement decisions in Australia and internationally.
